# Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes

> **NCT02089126** · PHASE3 · UNKNOWN · sponsor: **LG Life Sciences** · enrollment: 230 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Gemigliptin/Glimepiride combination

## Key facts

- **NCT ID:** NCT02089126
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2016-09
- **Final completion:** —
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2014-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089126, "Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02089126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*